Barrecheguren Miriam, Pinto Lancelot, Mostafavi-Pour-Manshadi Seyed-Mohammad-Yousof, Tan Wan C, Li Pei Z, Aaron Shawn D, Benedetti Andrea, Chapman Kenneth R, Walker Brandie, Fitzgerald J Mark, Hernandez Paul, Maltais François, Marciniuk Darcy D, O'Donnell Denis E, Sin Don D, Bourbeau Jean
Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada.
Pneumology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Respirology. 2020 Aug;25(8):836-849. doi: 10.1111/resp.13780. Epub 2020 Feb 16.
Lack of consensus on diagnosis of ACO limits our understanding of the impact, management and outcomes of ACO. The present observational study aims to describe the prevalence, clinical characteristics and course of individuals with ACO based on various definitions used in clinical practice.
We included individuals with COPD from the prospective, multisite CanCOLD study and defined subjects with ACO using seven definitions commonly used in the literature.
Data including questionnaires, lung function and CT scans were analysed from 522 individuals with COPD who were randomly recruited from the population. Among them, 264 fulfilled at least one of the seven definitions of ACO. Prevalence of ACO varied from 3.8% to 31%. Regardless of the definition, individuals with ACO had worse outcomes (lung function and higher percentage of fast decliners, symptoms and exacerbations, health-related quality of life and comorbidities) than the remaining patients with COPD. Conversely, patients with non-ACO had higher emphysema and bronchiolitis scores. The three definitions that included atopy and/or physician diagnosis of asthma identified subjects who differed significantly from patients with COPD. The two ACO definitions with post-bronchodilator reversibility were concordant with COPD and were the least stable, with less than 50% of the patients from each group maintaining reversibility over visits.
Atopy and physician-diagnosed asthma are more distinguishing characteristics to identify ACO. This finding needs to be validated using measures of airway inflammation and other specific biomarkers.
对慢性阻塞性肺疾病重叠综合征(ACO)诊断缺乏共识限制了我们对ACO的影响、管理及预后的理解。本观察性研究旨在基于临床实践中使用的各种定义描述ACO患者的患病率、临床特征及病程。
我们纳入了前瞻性、多中心加拿大慢性阻塞性肺疾病观察研究(CanCOLD)中的慢性阻塞性肺疾病(COPD)患者,并使用文献中常用的七种定义来界定ACO患者。
对从人群中随机招募的522例COPD患者的问卷、肺功能及CT扫描数据进行了分析。其中,264例符合ACO的七种定义中的至少一种。ACO的患病率从3.8%至31%不等。无论采用哪种定义,ACO患者的预后(肺功能、快速肺功能下降者的更高比例、症状及急性加重、健康相关生活质量及合并症)均比其余COPD患者更差。相反,非ACO患者的肺气肿和细支气管炎评分更高。包含特应性和/或医生诊断哮喘的三种定义所确定的受试者与COPD患者有显著差异。两种采用支气管扩张剂后可逆性的ACO定义与COPD一致,且最不稳定,每组中不到50%的患者在随访期间维持可逆性。
特应性和医生诊断的哮喘是识别ACO更具鉴别性的特征。这一发现需要通过气道炎症测量及其他特定生物标志物进行验证。